06 May 2021
Posted in Pharma
Diagnosed prevalent cases of CKD in the US projected to increase by 15.90% by 2030, says GlobalData
Diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets (7MM*) combined is expected to increase from 8.57 million cases in 2020 to 9.44 million in 2030, at an annual growth rate (AGR) of 1.02%, according to GlobalData, a leading data and analytics company.
Of the 7MM, the diagnosed prevalent cases of CKD in the US are expected to increase at an AGR of 1.59% between 2020 and 2030, followed by Spain (1.51%), and France (1.19%).
GlobalData’s latest report, ‘CKD – Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia: Epidemiology Forecast to 2030’, notes that the major drivers for the spike in the diagnosed prevalent cases of CKD in the US and the 7MM combined is attributable to the aging population combined with population genetics and other risk factors. Factors such as race, gender, age and family history are highly linked to CKD. Moreover, smoking, obesity, hypertension and diabetes mellitus can also increase the risk for CKD.
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, comments: “CKD is largely an asymptomatic condition that damages the kidneys and leads to the loss of kidney function over time. Currently, there is no cure for CKD; however, treatments can slow the progression of the disease. In the advanced stages of the disease CKD patients are advised to undergo renal replacement therapy (RRT) when the kidneys fail. Another way to reduce the burden of CKD would be early intervention. In order to achieve this, it is important to identify individuals with increased risk for CKD. Determining serum creatinine levels and urinalysis in patients with CKD risk will usually be sufficient for initial screening.”
*7MM: The US, France, Germany, Italy, Spain, the UK, and Japan